- Home
- NRDS vs TNGX Comparison
NRDS vs TNGX Comparison
Compare NRDS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- TNGX
- Stock Information
- Founded
- NRDS 2009
- TNGX 2014
- Country
- NRDS United States
- TNGX United States
- Employees
- NRDS N/A
- TNGX N/A
- Industry
- NRDS EDP Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NRDS Technology
- TNGX Health Care
- Exchange
- NRDS Nasdaq
- TNGX Nasdaq
- Market Cap
- NRDS 785.4M
- TNGX 723.2M
- IPO Year
- NRDS 2021
- TNGX N/A
- Fundamental
- Price
- NRDS $10.42
- TNGX $6.90
- Analyst Decision
- NRDS Buy
- TNGX Strong Buy
- Analyst Count
- NRDS 5
- TNGX 6
- Target Price
- NRDS $13.80
- TNGX $10.00
- AVG Volume (30 Days)
- NRDS 596.5K
- TNGX 1.9M
- Earning Date
- NRDS 08-07-2025
- TNGX 08-05-2025
- Dividend Yield
- NRDS N/A
- TNGX N/A
- EPS Growth
- NRDS N/A
- TNGX N/A
- EPS
- NRDS 0.60
- TNGX N/A
- Revenue
- NRDS $771,200,000.00
- TNGX $24,296,000.00
- Revenue This Year
- NRDS $18.07
- TNGX N/A
- Revenue Next Year
- NRDS $8.22
- TNGX N/A
- P/E Ratio
- NRDS $17.38
- TNGX N/A
- Revenue Growth
- NRDS 28.75
- TNGX N/A
- 52 Week Low
- NRDS $7.55
- TNGX $1.03
- 52 Week High
- NRDS $16.45
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- NRDS 50.56
- TNGX 56.63
- Support Level
- NRDS $9.89
- TNGX $6.60
- Resistance Level
- NRDS $10.31
- TNGX $7.42
- Average True Range (ATR)
- NRDS 0.39
- TNGX 0.47
- MACD
- NRDS 0.00
- TNGX -0.04
- Stochastic Oscillator
- NRDS 69.44
- TNGX 57.20
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.